BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22639986)

  • 1. Prospective prediction of viral suppression and immune response nine months after ART initiation in Seattle, WA.
    Simoni JM; Yard SS; Huh D
    AIDS Care; 2013; 25(2):181-5. PubMed ID: 22639986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
    Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
    JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral treatment adherence as a mediating factor between psychosocial variables and HIV viral load.
    Attonito J; Dévieux JG; Lerner BD; Hospital MM; Rosenberg R
    J Assoc Nurses AIDS Care; 2014; 25(6):626-37. PubMed ID: 25305029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships.
    Mujugira A; Celum C; Tappero JW; Ronald A; Mugo N; Baeten JM
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):148-54. PubMed ID: 26670218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
    Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
    Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
    JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana.
    Obiri-Yeboah D; Pappoe F; Baidoo I; Arthur F; Hayfron-Benjamin A; Essien-Baidoo S; Kwakye-Nuako G; Ayisi Addo S
    BMC Infect Dis; 2018 May; 18(1):230. PubMed ID: 29783953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.
    Zheng L; Bosch RJ; Chan ES; Read S; Kearney M; Margolis DM; Mellors JW; Eron JJ; Gandhi RT;
    Antivir Ther; 2013; 18(1):39-43. PubMed ID: 22914318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India.
    Rajasekaran S; Jeyaseelan L; Raja K; Vijila S; Krithigaipriya KA; Kuralmozhi R
    J Postgrad Med; 2009; 55(4):261-6. PubMed ID: 20083872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.
    Robbins GK; Cohn SE; Harrison LJ; Smeaton L; Moran L; Rusin D; Dehlinger M; Flynn T; Lammert S; Wu AW; Safren SA; Reynolds NR
    HIV Clin Trials; 2016 Jul; 17(4):165-72. PubMed ID: 27347650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary randomized controlled trial of a nurse-delivered medication adherence intervention among HIV-positive outpatients initiating antiretroviral therapy in Beijing, China.
    Simoni JM; Chen WT; Huh D; Fredriksen-Goldsen KI; Pearson C; Zhao H; Shiu CS; Wang X; Zhang F
    AIDS Behav; 2011 Jul; 15(5):919-29. PubMed ID: 20957423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating antiretroviral therapy during HIV infection: confusion and clarity.
    Pomerantz RJ
    JAMA; 2001 Nov; 286(20):2597-9. PubMed ID: 11722276
    [No Abstract]   [Full Text] [Related]  

  • 20. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.
    ; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M
    AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.